162 related articles for article (PubMed ID: 31611801)
1. Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis.
Kuo J; Serrano SS; Grönberg A; Massoumi R; Hansson MJ; Gallay P
Front Pharmacol; 2019; 10():1129. PubMed ID: 31611801
[TBL] [Abstract][Full Text] [Related]
2. Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
Stauffer WT; Bobardt M; Ure DR; Foster RT; Gallay P
PLoS One; 2024; 19(4):e0301711. PubMed ID: 38573968
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.
Simón Serrano S; Grönberg A; Longato L; Rombouts K; Kuo J; Gregory M; Moss S; Elmér E; Mazza G; Gallay P; Pinzani M; Hansson MJ; Massoumi R
Cells; 2019 Nov; 8(11):. PubMed ID: 31717385
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
5. [Establishment and evaluation of a mouse model of nonalcoholic steatohepatitis-related hepatocellular carcinoma].
Luo Y; Yang WJ; Chen JY; Zhang J; Zeng XD; Zhuang ZJ; Zang SF; Zhou G; Di CH; Shi JP
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):279-84. PubMed ID: 27470627
[TBL] [Abstract][Full Text] [Related]
6. Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors.
Zheng Q; Kawaguchi M; Mikami H; Diao P; Zhang X; Zhang Z; Nakajima T; Iwadare T; Kimura T; Nakayama J; Tanaka N
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509405
[TBL] [Abstract][Full Text] [Related]
7. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
9. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
[TBL] [Abstract][Full Text] [Related]
10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
12. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice.
Iida A; Kuranuki S; Yamamoto R; Uchida M; Ohta M; Ichimura M; Tsuneyama K; Masaki T; Seike M; Nakamura T
Exp Anim; 2019 Nov; 68(4):417-428. PubMed ID: 31155606
[TBL] [Abstract][Full Text] [Related]
13. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
14. The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice.
Akai H; Kiryu S; Ohta Y; Yasaka K; Nakano Y; Inoue Y; Ohtomo K
Magn Reson Imaging; 2017 May; 38():123-128. PubMed ID: 28062263
[TBL] [Abstract][Full Text] [Related]
15. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
Jojima T; Tomotsune T; Iijima T; Akimoto K; Suzuki K; Aso Y
Diabetol Metab Syndr; 2016; 8():45. PubMed ID: 27462372
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
19. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
20. Neonatal monosodium glutamate treatment causes obesity, diabetes, and macrovesicular steatohepatitis with liver nodules in DIAR mice.
Tsuneyama K; Nishida T; Baba H; Taira S; Fujimoto M; Nomoto K; Hayashi S; Miwa S; Nakajima T; Sutoh M; Oda E; Hokao R; Imura J
J Gastroenterol Hepatol; 2014 Sep; 29(9):1736-43. PubMed ID: 24730643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
